The EMCDDA: your reference point on drugs in Europe

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) was established in 1993. Inaugurated in Lisbon in 1995, it is one of the European Union's (EU) decentralised agencies.

The EMCDDA provides the EU and its Member States with a factual overview of European drug problems and a solid evidence base to support the drugs debate. Today it offers policymakers the data they need for drawing up informed drug laws and strategies. It also helps professionals and practitioners working in the field pinpoint best practice and new areas of research.

The EMCDDA works on the principle that sound information is the key to an effective strategy on drugs. Although it does not propose policy, the agency has a clear impact on decision-making through the analyses, standards and tools it provides.

The Reitox network

Reitox is the European information network on drugs and drug addiction created at the same time as the EMCDDA. Members of the Reitox network are designated national institutions or agencies responsible for data collection and reporting on drugs and drug addiction. These institutions are called 'national focal points' or 'national drug observatories'.

The EMCDDA-IPA project

Time frame: 2012–14Budget: EUR 900 000

- Beneficiaries: Albania, Bosnia and Herzegovina, Croatia, Former Yugoslav Republic of Macedonia, Iceland, Kosovo*, Montenegro, Serbia and Turkey.
- Objective: the overall project objective is to support the IPA beneficiaries in their preparation for participation in the work of the EMCDDA and the Reitox network.

In order to achieve this, the project has defined a set of measurable and specific objectives:

- To consolidate the cooperation between the EMCDDA and each beneficiary at institutional level
- To foster scientific cooperation in relation to data collection, analysis and interpretation
- To develop, expand and promote the added value of the cooperation

The project is implemented by the EMCDDA. The project is financed through the Instrument of Pre-accession Assistance (IPA) of Directorate-General Enlargement of the European Commission. It is a continuation of previous projects implemented over the last seven years. The overall project management is ensured by the EMCDDA's Reitox and international cooperation unit.

For more details on IPA, see: http://ec.europa.eu/enlargement/how-does-it-work/financial-assistance/instrument-pre-accession en.htm

EMCDDA-IPA project partners

National correspondents/Heads of focal points

Each IPA beneficiary has nominated a Head of focal point or a National correspondent for this project. She/he will be the EMCDDA's counterpart for organising activities at national level. The EMCDDA contact points are located in:

- Albania: National Institute of Public Health
- Bosnia and Herzegovina: (national correspondent not yet officially appointed)
- Croatia: Government Office for Combating Narcotic Drugs Abuse (National focal point)
- Former Yugoslav Republic of Macedonia: Ministry of Health (National focal point)
- Kosovo*: Ministry of Internal Affairs
- Montenegro: (national correspondent not yet officially appointed)
- Serbia: Institute of Public Health
- Turkey: Turkish Monitoring Centre for Drugs and Drug Addiction (TUBIM — National focal point)

Reitox coaches

The EMCDDA has established a Reitox coaching system whereby Heads of National focal points act as coaches to IPA beneficiaries. Once selected, the Head of focal point assists a partner beneficiary and the EMCDDA in the coordination and implementation of IPA project activities.

Outputs from previous projects

- National country overviews
- National information maps
- National action plans on drug information systems
- National reports on the drug situation (2011)
- School Surveys on alcohol and other drugs (ESPAD)
- Estimating problem drug use in Ankara, Istanbul and Izmir (Turkey)
- Survey on substance use among the general population in Croatia
- Evaluation of the national strategy on combating drugs abuse in Croatia 2006–12
- EMCDDA protocols, guidelines and key reports in national languages

EMCDDA-IPA expected results

- Establishment or consolidation of a National focal point
- Increased availability of studies, monitoring of drug-related issues in line with EMCDDA standards
- Increased opportunities of collaboration with the Reitox network

For more information: www.emcdda.europa.eu

Geographical coverage



The EMCDDA-IPA project covers the following partners:

Acceding country: Croatia

Candidate countries: Former Yugoslav Republic of Macedonia, Iceland, Montenegro, Serbia, Turkey

Potential candidate countries: Albania, Bosnia and Herzegovina, Kosovo*



EMCDDA-IPA PROJECT

PREPARING IPA BENEFICIARIES FOR THEIR PARTICIPATION IN THE WORK OF THE EMCDDA

2012-14



European Monitoring Centre for Drugs and Drug Addiction

Cais do Sodré 1249-289 Lisbon, Portugal Tel. + 351 211 21 02 00 Fax. +351 213 58 44 40

ipa@emcdda.europa.eu • www.emcdda.europa.eu